Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT01290302 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza® versus subcutaneous Luitpold Azacitidine.

NCT ID: NCT01284010 Completed - Leukemia Clinical Trials

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

Start date: February 2011
Phase:
Study type: Observational

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood and bone marrow samples from patients with acute lymphoblastic leukemia.

NCT ID: NCT01279473 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

NCT ID: NCT01279252 Completed - Clinical trials for Chronic Lymphocytic Leukaemia (CLL)

CLL Empirical Antibiotic Regimen

CLEAR
Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether patients with previously untreated, early stage CLL respond to empirical broad spectrum antibiotics and therefore test the hypothesis that occult bacterial infections are involved in the induction and maintenance of CLL.

NCT ID: NCT01279096 Completed - Clinical trials for Acute Lymphoid Leukemia Relapse

Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia

Vandevol
Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone and to assess the feasibility and safety of this combination regimen to treat children with high risk relapsed or refractory acute lymphoblastic leukemia (ALL).

NCT ID: NCT01273766 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Start date: January 2011
Phase: Phase 2
Study type: Interventional

RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.

NCT ID: NCT01272817 Completed - Breast Cancer Clinical Trials

Nonmyeloablative Allogeneic Transplant

Mini-allo
Start date: October 2001
Phase: N/A
Study type: Interventional

Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.

NCT ID: NCT01269385 Completed - Clinical trials for Refractory Chronic Lymphocytic Leukemia

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic lymphocytic leukemia (CLL) cells and are effective therapies for this disease. Biological therapies, such as Imprime PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose), may stimulate the immune system in different ways and help monoclonal antibodies kill CLL cells. Giving PGG beta-glucan together with alemtuzumab and rituximab could make therapy with monoclonal antibodies, such as alemtuzumab and rituximab, more effective. PURPOSE: This phase I/II trial is studying the side effects and best dose of PGG beta-glucan when given together with alemtuzumab and rituximab and to see how well it works in treating patients with earlier stage high-risk chronic lymphocytic leukemia.

NCT ID: NCT01266083 Completed - Clinical trials for Acute Myeloid Leukemia

WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

To determine whether the WT1 vaccine causes an immune response which is safe and able to keep the leukemia from coming back.

NCT ID: NCT01263704 Completed - Clinical trials for Lymphocytic Leukemia, Chronic

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

Start date: July 17, 2011
Phase: Phase 2
Study type: Interventional

This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65 years) with chronic lymphocytic leukemia. Patients will receive six 28-day cycles of treatment with Mabthera/Rituxan (375 mg/m2 intravenously [iv] Day 0 of cycle 1, 500 mg/m2 iv Day 1 of cycles 2-6), fludarabine (12.5 mg/m2/d iv Days 1-3, cycles 1-6) and cyclophosphamide (150 mg/m2/d iv Days 1-3, cycles 1-6). Anticipated time on study treatment is 6 months, with a 30-month follow-up period.